Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


First France, Now Germany Pulls Takeda's Actos For New Patients On Bladder Cancer Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

Withdrawals call into question the remaining revenues the diabetes product can generate before its main patents expire.

You may also be interested in...

Doctor’s Letter Triggers Pioglitazone Ban; India’s Health Ministry Under Fire

The waffling of India’s drug regulatory agency on the pioglitazone ban reveals cracks in the regulatory system.

Abrupt Ban On Pioglitazone Angers Industry, Medical Experts; Is A Rollback In The Cards?

Major players in the Indian drug industry expressed disappointment on the unilateral decision of the health ministry to ban pioglitazone and its combinations.

EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective

Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts